This Analyst Thinks Menlo (MNLO) Stock Is Poised for Growth
This Analyst Thinks Menlo (MNLO) Stock Is Poised for Growth


2020 has been kind to small-cap biotechs. Some have spiked upwards dramatically this year, mostly on the hope of finding solutions to COVID-19, be it a treatment or vaccine. Those who haven’t gotten in on the action yet still yearn to join the fray, might justifiably feel a sense of apprehension. An investment in a stock that has already posted double, or in some cases, triple digit gains feels like risky business.
However, the volatile biotech world always presents fresh opportunities. Northland Securities analyst Tim Chiang argues the case for dermatology-focused Menlo Therapeutics (MNLO). Shares are down by a depressing 49% so far this year, but Chiang is anticipating hefty returns from the small-cap.
Based on what, you ask?
Last Friday, the FDA gave its nod of approval for Zilxi, Menlo’s topical 1.5% minocycline treatment for adults with rosacea. Rosacea is a skin condition marked by redness and clearly noticeable blood vessels on the face.
Additionally, Zilxi is the first topical foam formulation containing minocycline to receive the FDA’s stamp of approval, and Chiang believes that by 2026, the product’s sales could reach $120 million. That will make it Menlo’s second largest selling product, only behind acne treatment Amzeeq, which is expected to reach sales of $272 million by 2026.
The company plans to launch Zilxi in 4Q20. Based on Chiang’s calculations, the acne and rosacea treatment markets are substantial, believing the former’s TAM (total addressable market) to be worth $5 billion, and the latter around $1 billion.
Chiang opined, “With MNLO's focused 50-person sales force already in place, we think the Co. will have the benefit of having two new topical foam products (both containing low doses of minocycline) to detail to dermatologists. We believe the recent approval of ZIlxi adds a complementary product to MNLO's dermatology arsenal. Combined with Amzeeq, we estimate total revenues are likely to increase to $77 million in CY21, and $140 million in CY22.”
All of the above prompted Chiang to reiterate an Outperform rating on Menlo. Adding to the good news, he bumped up the price target from $3.50 to $6. There’s upside of 164%, should Chiang’s target be met over the coming months. (To watch Chiang’s track record, click here)
The rest of the Street is also optimistic. Based solely on Buys – 8, in fact - Menlo has a Strong Buy consensus rating. With an average price target of $6.93, the analysts forecast gains in the shape of 197% over the next 12 months. (See Menlo stock analysis at TipRanks)

To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
The post This Analyst Thinks Menlo (MNLO) Stock Is Poised for Growth appeared first on TipRanks Financial Blog.
Spread & Containment
Repeated COVID-19 Vaccination Weakens Immune System: Study
Repeated COVID-19 Vaccination Weakens Immune System: Study
Authored by Zachary Stieber via The Epoch Times (emphasis ours),
Repeated COVID-19…

Authored by Zachary Stieber via The Epoch Times (emphasis ours),
Repeated COVID-19 vaccination weakens the immune system, potentially making people susceptible to life-threatening conditions such as cancer, according to a new study.
Multiple doses of the Pfizer or Moderna COVID-19 vaccines lead to higher levels of antibodies called IgG4, which can provide a protective effect. But a growing body of evidence indicates that the “abnormally high levels” of the immunoglobulin subclass actually make the immune system more susceptible to the COVID-19 spike protein in the vaccines, researchers said in the paper.
They pointed to experiments performed on mice that found multiple boosters on top of the initial COVID-19 vaccination “significantly decreased” protection against both the Delta and Omicron virus variants and testing that found a spike in IgG4 levels after repeat Pfizer vaccination, suggesting immune exhaustion.
Studies have detected higher levels of IgG4 in people who died with COVID-19 when compared to those who recovered and linked the levels with another known determinant of COVID-19-related mortality, the researchers also noted.
A review of the literature also showed that vaccines against HIV, malaria, and pertussis also induce the production of IgG4.
“In sum, COVID-19 epidemiological studies cited in our work plus the failure of HIV, Malaria, and Pertussis vaccines constitute irrefutable evidence demonstrating that an increase in IgG4 levels impairs immune responses,” Alberto Rubio Casillas, a researcher with the biology laboratory at the University of Guadalajara in Mexico and one of the authors of the new paper, told The Epoch Times via email.
The paper was published by the journal Vaccines in May.
Pfizer and Moderna officials didn’t respond to requests for comment.
Both companies utilize messenger RNA (mRNA) technology in their vaccines.
Dr. Robert Malone, who helped invent the technology, said the paper illustrates why he’s been warning about the negative effects of repeated vaccination.
“I warned that more jabs can result in what’s called high zone tolerance, of which the switch to IgG4 is one of the mechanisms. And now we have data that clearly demonstrate that’s occurring in the case of this as well as some other vaccines,” Malone, who wasn’t involved with the study, told The Epoch Times.
“So it’s basically validating that this rush to administer and re-administer without having solid data to back those decisions was highly counterproductive and appears to have resulted in a cohort of people that are actually more susceptible to the disease.”
Possible Problems
The weakened immune systems brought about by repeated vaccination could lead to serious problems, including cancer, the researchers said.
Read more here...
Spread & Containment
Robert F. Kennedy Jr. Banned By Major Social Media Site, Campaign Pages Blocked
Robert F. Kennedy Jr. Banned By Major Social Media Site, Campaign Pages Blocked
Authored by Jack Phillips via The Epoch Times (emphasis ours),
Twitter…

Authored by Jack Phillips via The Epoch Times (emphasis ours),
Twitter owner Elon Musk invited Democrat presidential candidate Robert F. Kennedy Jr. for a discussion on his Twitter Spaces after Kennedy said his campaign was suspended by Meta-owned Instagram.
“Interesting… when we use our TeamKennedy email address to set up @instagram accounts we get an automatic 180-day ban. Can anyone guess why that’s happening?” he wrote on Twitter.
An accompanying image shows that Instagram said it “suspended” his “Team Kennedy” account and that there “are 180 days remaining to disagree” with the company’s decision.
In response to his post, Musk wrote: “Would you like to do a Spaces discussion with me next week?” Kennedy agreed, saying he would do it Monday at 2 p.m. ET.
Hours later, Kennedy wrote that Instagram “still hasn’t reinstated my account, which was banned years ago with more than 900k followers.” He argued that “to silence a major political candidate is profoundly undemocratic.”
“Social media is the modern equivalent of the town square,” the candidate, who is the nephew of former President John F. Kennedy, wrote. “How can democracy function if only some candidates have access to it?”
The Epoch Times approached Instagram for comment.
Interesting… when we use our TeamKennedy email address to set up @instagram accounts we get an automatic 180-day ban. Can anyone guess why that’s happening? pic.twitter.com/0G8oRnoXTv
— Robert F. Kennedy Jr (@RobertKennedyJr) June 2, 2023
It’s not the first time that either Facebook or Instagram has taken action against Kennedy. In 2021, Instagram banned him from posting claims about vaccine safety and COVID-19.
After he was banned by the platform, Kennedy said that his Instagram posts raised legitimate concerns about vaccines and were backed by research. His account was banned just days after Facebook and Instagram announced they would block the spread of what they described as misinformation about vaccines, including research saying the shots cause autism, are dangerous, or are ineffective.
“This kind of censorship is counterproductive if our objective is a safe and effective vaccine supply,” he said at the time.
Read more here...
Spread & Containment
Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction
Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction
Authored by Jessie Zhang via Thje Epoch…

Authored by Jessie Zhang via Thje Epoch Times (emphasis ours),
An Australian and Swedish investigation has found that among the hundreds of COVID-19 research papers that have been withdrawn, a retracted study linking the drug hydroxychloroquine to increased mortality was the most cited paper.
With 1,360 citations at the time of data extraction, researchers in the field were still referring to the paper “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” long after it was retracted.
Authors of the analysis involving the University of Wollongong, Linköping University, and Western Sydney Local Health District wrote (pdf) that “most researchers who cite retracted research do not identify that the paper is retracted, even when submitting long after the paper has been withdrawn.”
“This has serious implications for the reliability of published research and the academic literature, which need to be addressed,” they said.
“Retraction is the final safeguard against academic error and misconduct, and thus a cornerstone of the entire process of knowledge generation.”
Scientists Question Findings
Over 100 medical professionals wrote an open letter, raising ten major issues with the paper.
These included the fact that there was “no ethics review” and “unusually small reported variances in baseline variables, interventions and outcomes,” as well as “no mention of the countries or hospitals that contributed to the data source and no acknowledgments to their contributions.”

Other concerns were that the average daily doses of hydroxychloroquine were higher than the FDA-recommended amounts, which would present skewed results.
They also found that the data that was reportedly from Australian patients did not seem to match data from the Australian government.
Eventually, the study led the World Health Organization to temporarily suspend the trial of hydroxychloroquine on COVID-19 patients and to the UK regulatory body, MHRA, requesting the temporary pause of recruitment into all hydroxychloroquine trials in the UK.
France also changed its national recommendation of the drug in COVID-19 treatments and halted all trials.
Currently, a total of 337 research papers on COVID-19 have been retracted, according to Retraction Watch.
Further retractions are expected as the investigation of proceeds.
-
Spread & Containment4 hours ago
Robert F. Kennedy Jr. Banned By Major Social Media Site, Campaign Pages Blocked
-
Spread & Containment7 hours ago
Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction
-
Spread & Containment14 hours ago
Mark Zuckerberg Moves to Kill a Pandemic Habit
-
International15 hours ago
Complying, Not Defying: Twitter And The EU Censorship Code
-
Government10 hours ago
Biden Signs Debt Ceiling Bill, Ending Monthslong Political Battle
-
Uncategorized7 hours ago
Warren Buffett’s Advice on Stocks vs. Bonds
-
Spread & Containment11 hours ago
Mark Zuckerberg Makes a Bold Move
-
Spread & Containment3 hours ago
Repeated COVID-19 Vaccination Weakens Immune System: Study